Enhanced Heart Failure Management: Impact of the therapeutic unit for heart failure (TUNI-HF) on mid-term prognosis

##plugins.themes.academic_pro.article.sidebar##

Published Jun 1, 2025
https://doi.org/10.62438/tunismed.v103i6.5449
Download
pdf
Vol. 103 No. 6 (2025): Tunis Med June 2025

##plugins.themes.academic_pro.article.main##

Houdhayfa Hermassi
Cardiology department, Military hospital of Tunis, Tunisia
Houssem Ben Ayed
Cardiology department, Military hospital of Tunis, Tunisia
Houaida Mahfoudhi
Cardiology department, Military hospital of Tunis, Tunisia
Nadhem Hajlaoui
Cardiology department, Military hospital of Tunis, Tunisia
Abdedayem Haggui
Cardiology department, Military hospital of Tunis, Tunisia
Wafa Fehri
Cardiology department, Military hospital of Tunis, Tunisia

Abstract

Background: Chronic heart failure (CHF) is a global and increasing problem responsible of uncontrolled rates of mortality and readmission. A therapeutic Unit of heart failure (TUNI-HF) was established to assume a treatment optimization, comorbidities management and education in order to improve heart failure (HF) prognosis.


Aim: This study aimed to describe the impact of the TUNI-HF on treatment optimization, mortality and readmission rates at 12 months in patients with heart failure with reduced ejection fraction (HFrEF).


Methods:  A retrospective study was conducted in the military hospital of Tunis, Tunisia. Two groups were compared: Group “C” included patients followed from March 2018 for 12 months with usual care. Group “U” included patients followed from Mars 2021 for 12 months in the TUNI-HF.


Results: Groups “C” and “U” enrolled 108 and 110 patients respectively. At baseline, patients’ characteristics were comparable. Prescription rates of guideline directed medical treatment (GDMT) at optimal doses were low in two groups. After 12 months, prescription rates of beta-blockers (BB) and mineralocorticoid receptor antagonist (MRA) were higher in group “U”. In addition, optimal doses of BB, renin angiotensin aldosterone system inhibitors (RAASI) and MRA were more achieved in the same group “U”. Loop diuretics were less prescribed in the group “U” and cardiac implantable devices rate was higher in the same group. Kaplan Meier analysis showed significantly lower rates of readmission and all-cause mortality rates in the group “U”.


Conclusion: The management of HF in a specialized unit, compared with usual care,...(abstract truncated at 250 words).

Keywords:

Hospital Unit, Mid term prognosis, Management, Heart failure with reduced ejection fraction

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 10 nov 2018;392(10159):1789‑858.
  2. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. août 2020;22(8):1342‑56.
  3. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 1 déc 2022;118(17):3272‑87.
  4. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. nov 2019;21(11):1306‑25.
  5. Abid L, Charfeddine S, Kammoun I, Ben Halima M, Ben Slima H, Drissa M, et al. Epidemiology of heart failure and long-term follow-up outcomes in a north-African population: Results from the NAtionalTUnisianREgistry of Heart Failure (NATURE-HF). Kilic A, éditeur. PLoS ONE. 20 mai 2021;16(5):e0251658.
  6. Albert C, Estep JD. Economic Impact of Chronic Heart Failure Management in Today’s Cost-Conscious Environment. Card ElectrophysiolClin. mars 2019;11(1):1‑9.
  7. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 21 sept 2021;42(36):3599‑726.
  8. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 3 mai 2022;145(18):e895‑1032.
  9. National Authority for Evaluation and Accreditation in Health. Update of the Guide: Management of Chronic Heart Failure in Adults. [Online]. June 2022 [Accessed July 22,2024]. Available at: https://www.ineas.tn/actualite/La-mise-%C3%A0-jour-du-guide-de-pratique-clinique.
  10. Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. Am J RespirCrit Care Med. 1 mai 2003;167(9):1287.
  11. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. EurRespir J. déc 2014;44(6):1428‑46.
  12. National Observatory of New and Emerging Diseases. Bulletin de veille COVID-19 à la date du 12 Décembre 2021, ONMNE | ONMNE [Internet]. 2021 [cité 26 mai 2024]. Available at: https://www.onmne.tn/?p=15695
  13. Cherif I, Kharroubi G, Chaabane S, Yazidi R, Dellagi M, Snoussi MA, et al. COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City Tunis. Diagnostics (Basel). 13 avr 2022;12(4):971.
  14. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. European Journal of Heart Failure. 2016;18(6):613‑25.
  15. Teng THK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. The Lancet Global Health. 1 sept 2018;6(9):e1008‑18.
  16. Peri-Okonny P, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights from the CHAMP-HF Registry. JACC Heart Fail. avr 2019;7(4):350‑8.
  17. Brunner-La Rocca HP, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma HJ, Westendorp PH, et al. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. JACC: Heart Failure. 1 janv 2019;7(1):13‑21.
  18. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. European Heart Journal. 21 juin 2017;38(24):1883‑90.
  19. Savarese G, Lindberg F, Cannata A, Chioncel O, Stolfo D, Musella F, et al. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 22 mai 2024;
  20. Thomas R, Huntley A, Mann M, Huws D, Paranjothy S, Elwyn G, et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart. 15 févr 2013;99(4):233‑9.
  21. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet. déc 2022;400(10367):1938‑52.
  22. Cox ZL, Collins SP, Hernandez GA, McRae AT, Davidson BT, Adams K, et al. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. Journal of the American College of Cardiology. 9 avr 2024;83(14):1295‑306.
  23. Liu C, Ferrari VA, Han Y. Cardiovascular Magnetic Resonance Imaging and Heart Failure. CurrCardiol Rep. 8 mars 2021;23(4):35.
  24. Zuily S, Jourdain P, Decup D, Agrinier N, Loiret J, Groshens S, et al. Impact of heart failure management unit on heart failure-related readmission rate and mortality. Archives of Cardiovascular Diseases. févr 2010;103(2):90‑6.
  25. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. Cochrane Database Syst Rev. 8 janv 2019;2019(1):CD002752.
  26. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. European Journal of Heart Failure. 2017;19(11):1427‑43.
  27. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar‐Jacob JM. Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta‐Analysis of Controlled Trials. J Am Heart Assoc. 17 juin 2016;5(6):e002606.
  28. Pagnesi M, Metra M, Cohen-Solal A, Edwards C, Adamo M, Tomasoni D, et al. Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction. Journal of the American College of Cardiology. 6 juin 2023;81(22):2131‑44.
  29. Janse RJ, Fu EL, Dahlström U, Benson L, Lindholm B, van Diepen M, et al. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician’s prescriptions to patient’s dispensations, medication adherence and persistence. Eur J Heart Fail. nov 2022;24(11):2185‑95.
  30. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am CollCardiol. 21 mai 2019;73(19):2365‑83.
  31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 14 juill 2016;37(27):2129‑200.